Flat dose intravenous immunoglobulin (IVIG) for primary infection prophylaxis after CAR-T for B-cell non-Hodgkin lymphoma (B-NHL).
Spencer Lessans(Vanderbilt University Medical Center), Vivek Patel(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Adetola A. Kassim(Vanderbilt University), Muhamed Baljević(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), David Morgan(Vanderbilt University Medical Center), Eden Biltibo(Vanderbilt University Medical Center), Bipin N. Savani(Vanderbilt University Medical Center), Morgan L. Zenner(University of Illinois Chicago)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782